Glenmark Pharmaceuticals Annual Results FY26

Consolidated Revenue: ₹16,982.51 crore
Consolidated Net Profit: ₹1,362 crore

Reader Takeaway: Consolidated profit positive, but standalone loss and large exceptional charges pose pressure.

What just happened

Glenmark Pharmaceuticals reported its financial results for the year ended March 31, 2026. The company announced a consolidated net profit of ₹1,361.95 crore on revenue from operations of ₹16,982.51 crore. The total income stood at ₹17,443.13 crore. A significant factor influencing the results was exceptional items amounting to ₹2,266.08 crore.

Why this matters

Despite substantial exceptional charges, Glenmark managed to post a consolidated profit. These charges included provisions for U.S. lawsuits, inventory adjustments, and employee benefits linked to new labor codes. The recommended final dividend of ₹2.5 per equity share offers a direct return to shareholders. However, the standalone net loss of ₹200.80 crore indicates operational challenges at the core entity level.

The backstory

The company's financial performance in the current year reflects significant one-time expenses related to legal settlements and restructuring. These provisions are crucial for addressing past liabilities and streamlining operations.

What changes now

Investors will be looking for how these exceptional items impact future financial statements and the company's ability to generate sustainable profits. The dividend payout signals confidence in cash flows, even with the provisioning.

Risks to watch

Key concerns include the substantial exceptional charges which distort operational profitability. The standalone net loss highlights underlying performance issues that need addressing. Ongoing antitrust litigation in the U.S. remains a significant watch point for potential future financial impacts.

Peer comparison

(No specific peer data available in the filing to compare.)

Context metrics (time-bound)

• Consolidated Revenue (FY26): ₹16,982.51 crore
• Consolidated Net Profit (FY26): ₹1,362 crore
• Standalone Net Loss (FY26): ₹201 crore
• Dividend Recommendation: ₹2.5 per share
• Exceptional Items (Expense): ₹2,266.08 crore

What to track next

Investors should closely monitor the company's progress in resolving U.S. legal cases and the impact of restructuring on standalone performance. Future earnings reports will reveal the sustainability of profits post these exceptional charges.